RYAN KATIDES: Open Payments
NPI 1093315863 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,717 in 16 payments from 10 companies in 2025. Trend: 2023 $1,031 · 2024 $437 · 2025 $4,717
Speaker / faculty: $3,563Consulting: $750Food & beverage: $404
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $3,687 |
| AstraZeneca Pharmaceuticals LP | 1 | $750 |
| Astellas Pharma US Inc | 5 | $107 |
| Janssen Biotech, Inc. | 1 | $46 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Caris MPI, Inc. | 1 | $25 |
| BeOne Medicines USA, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $20 |
| Novocure Inc. | 1 | $18 |
| Novartis Pharmaceuticals Corporation | 1 | $17 |
Products named: Nubeqa, LYNPARZA, Xtandi, TECVAYLI, OPDIVO, MI CANCER SEEK, BRUKINSA, Fabhalta.
Industry payments across MA — which companies pay providers there.
